Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3491596 | 1.00 | KDM4E (0.32) | KDM4E | |
| SCHEMBL116655 | 0.98 | KDM4E (0.33) | KDM4E | |
| SCHEMBL819568 | 0.98 | KDM4E (0.33) | KDM4E | |
| Trimethylammonium SCHEMBL27436239 | 0.92 | KDM4E (0.31) | KDM4E | |
| Hydrochloric Acid SCHEMBL10322258 | 0.83 | GRIK1 (0.33) | — | |
| SCHEMBL6530950 | 0.81 | GRIK1 (0.34) | — | |
| SCHEMBL6513873 | 0.81 | GRIK1 (0.34) | — | |
| SCHEMBL1276175 | 0.80 | SLC1A3 (0.34) | — | |
| SCHEMBL29273109 | 0.79 | SLC22A16 (0.32) | — | |
| SCHEMBL6548783 | 0.78 | DPP4 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119837842-A | Nanometer transdermal delivery system based on superoxide dismutase and preparation method thereof | 上海交通大学 | 2025-04-18 | — | — | CN | claimed |
| EP-2012831-A2 | NANOGEL CONTRAST AGENTS FOR OPTICAL MOLECULAR IMAGING | Carestream Health, Inc. (US) | 2009-01-14 | — | — | EP | claimed |
| WO-2008036117-A2 | NANOGEL CONTRAST AGENTS FOR OPTICAL MOLECULAR IMAGING | CARESTREAM HEALTH, INC. (US) | 2008-03-27 | — | — | WO | claimed |
| US-20070237821-A1 | Nanogel-based contrast agents for optical molecular imaging | EASTMAN KODAK COMPANY | 2007-10-11 | — | — | US | claimed |
| EP-0599741-B1 | Photographic support material comprising an antistatic layer and a heat-thickening barrier layer | EASTMAN KODAK CO (US) | 1999-03-10 | — | — | EP | claimed |
| EP-0599741-A1 | Photographic support material comprising an antistatic layer and a heat-thickening barrier layer | EASTMAN KODAK COMPANY (US) | 1994-06-01 | — | — | EP | claimed |
| US-5221598-A | Vanadium pentoxide layer and overlying polyacrylamide layer | EASTMAN KODAK COMPANY (US) | 1993-06-22 | — | — | US | claimed |
| EP-0213896-B1 | ADHESION PROMOTING POLYMERIC MATERIALS | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1992-01-22 | — | — | EP | claimed |
| EP-0213896-A2 | Adhesion promoting polymeric materials | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1987-03-11 | — | — | EP | claimed |
| CN-119837822-B | Active ingredient hair follicle transdermal delivery system based on protein carrier | SHANGHAI JIAO TONG UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| WO-2025123597-A1 | PROTEIN CARRIER-BASED ACTIVE INGREDIENT TRANSDERMAL DELIVERY SYSTEM, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海交通大学 | 2025-06-19 | — | — | WO | disclosed |
| CN-119909174-A | Compositions, imaging agents, methods for obtaining data, providing and developing PDT, developing therapies and materials, evaluating subjects, MRI imaging and upgrading MRI, and MRI systems | 密歇根大学董事会 | 2025-05-02 | — | — | CN | disclosed |
| CN-119837820-A | Active ingredient transdermal delivery system based on protein carrier, and preparation method and application thereof | 上海交通大学 | 2025-04-18 | — | — | CN | disclosed |
| CN-119837822-A | Active ingredient hair follicle transdermal delivery system based on protein carrier | 上海交通大学 | 2025-04-18 | — | — | CN | disclosed |
| EP-0598788-A1 | POLYMERIC SCAVENGERS FOR OXIDIZED DEVELOPING AGENTS AND PHOTOGRAPHIC ELEMENTS CONTAINING THE SAME. | EASTMAN KODAK CO (US) | 1994-06-01 | — | — | EP | disclosed |
| US-5284714-A | Vanadium pentoxide antistatic layer, polyacrylamide overlayer | EASTMAN KODAK COMPANY (US) | 1994-02-08 | — | — | US | disclosed |
| US-5244763-A | Hydrophilic colloid layer, reducing agent comprising polymer with gallic acid or gallic acid derivative moieties | EASTMAN KODAK COMPANY (US) | 1993-09-14 | — | — | US | disclosed |
| US-5221598-A | Vanadium pentoxide layer and overlying polyacrylamide layer | EASTMAN KODAK COMPANY (US) | 1993-06-22 | — | — | US | disclosed |
| US-5198517-A | Reducing agents | EASTMAN KODAK COMPANY (US) | 1993-03-30 | — | — | US | disclosed |
| WO-1993003421-A1 | POLYMERIC SCAVENGERS FOR OXIDIZED DEVELOPING AGENTS AND PHOTOGRAPHIC ELEMENTS CONTAINING THE SAME | EASTMAN KODAK COMPANY (US) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070237821-A1 | Nanogel-based contrast agents for optical molecular imaging | MSN, F12, ZYX | KDM4E 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.